肝硬化血小板减少的病理生理发生机制

doi:10.3969/j.issn.1672-5069.2019.04.003

Abstract

Xiao Han, Wang Li. Mechanisms of thrombocytopenia in liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 462-465.

[1] Nomura S,Ogami K,Kawamura K,et al.Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. Exp Hematol,1997,25(7):565-572.
[2] Stoffel R,Wiestner A,Skoda RC,Thrombopoietin in thrombocytopenic mice:evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood,1996,87(2):567-573.
[3] Desmond R,Townsley DM,Dumitriu B,et al.Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood,2014,123(12):1818-1825.
[4] Majka M,Janowska-Wieczorek A,Ratajczak J,et al.Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood,2000,96(13):4142-4151.
[5] Li J,Xia Y,Kuter DJ.Interaction of thrombopoietin with the platelet c-mpl receptor in plasma:binding,internalization,stability and pharmacokinetics. Br J Haematol,1999. 106(2):345-356.
[6] Fielder PJ,Gurney AL,Stefanich E,et al.Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood,1996,87(6):2154-2161.
[7] Saur SJ,Sangkhae V,Geddis AE,et al.Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood,2010,115(6):1254-1263.
[8] Kubota Y,Arai T,Tanaka T,et al.Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation. Stem Cells,1996,14(4): 439-444.
[9] Cuong NT,Doi T,Matsushima-Nishiwaki R,et al. Thrombopoietin amplifies ADP-induced HSP27 phosphorylation in human platelets:importance of pre-treatment. Int J Mol Med,2013,31(6):1291-1297.
[10] Zeldis JB,Mugishima H,Steinberg HN,et al.In vitro hepatitis B virus infection of human bone marrow cells. J Clin Invest,1986,78(2): 411-417.
[11] El Barbary MA,Saad AE,Attia FM,et al.Thrombocytopenia in patients with chronic hepatitis C:a possible role of HCV on platelet progenitor cell maturation. Angiology,2010,61(3):304-313.
[12] Garcia-Suarez J,Burgaleta C,Hernanz N,et al.HCV-associated thrombocytopenia:clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol,2000,110(1):98-103.
[13] Joo EJ,Chang Y,Yeom JS,et al.Hepatitis B infection is associated with an increased incidence of thrombocytopenia in healthy adults without cirrhosis. J Viral Hepat,2017,24(3):253-258.
[14] Weksler BB.The pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther,2007,26(Suppl 1):13-19.
[15] Dai CY,Ho CK,Huang JF,et al.Hepatitis C virus viremia and low platelet count:a study in a hepatitis B & C endemic area in Taiwan. J Hepatol,2010,52(2):160-166.
[16] Girard DE,Kumar KL,McAfee JH. Hematologic effects of acute and chronic alcohol abuse. Hematol Oncol Clin North Am,1987,1(2):321-334.
[17] Emmons RV,Reid DM,Cohen RL,et al.Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood,1996,87(10):4068-4071.
[18] Temel T,Cansu DU,Temel HE,et al.Serum thrombopoietin levels and its relationship with thrombocytopenia in patients with cirrhosis. Hepat Mon,2014,14(5):e18556.
[19] El-Sayed R,El-Ela MA,El-Raziky MS,et al.Relation of serum levels of thrombopoietin to thrombocytopenia in extrahepatic portal vein obstruction versus cirrhotic children. J Pediatr Hematol Oncol,2011,33(7):e267-270.
[20] Peck-Radosavljevic M,Zacherl J,Meng YG,et al. Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver J Hepatol,1997,27(1):127-131.
[21] Zhang W,Nardi MA,Borkowsky W,et al.Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood,2009,113(17):4086-4093.
[22] Chiao EY,Engels EA,Kramer JR,et al.Risk of immune thrombocytopenic purpura and autoimmune hemolytic anemia among 120 908 US veterans with hepatitis C virus infection. Arch Intern Med,2009,169(4):357-363.
[23] Gemery JM,Forauer AR,Silas AM,et al.Hypersplenism in liver disease and SLE revisited:current evidence supports an active rather than passive process. BMC Hematol,2016,16(1):3.
[24] Jiang A,Zhang S,Li Z,et al.miR-615-3p promotes the phagocytic capacity of splenic macrophages by targeting ligand-dependent nuclear receptor corepressor in cirrhosis-related portal hypertension. 2011,236(6):672-680.
[25] Shelat SG,Ai J,Zheng XL.Molecular biology of ADAMTS13 and diagnostic utility of ADAMTS13 proteolytic activity and inhibitor assays. Semin Thromb Hemost,2005,31(6):659-672.
[26] Uemura M,Fujimura Y,Matsumoto M,et al.Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. Thromb Haemost,2008,99(6):1019-1029.
[27] Uemura M,Fujimura Y,Ko S,et al.Pivotal role of ADAMTS13 function in liver diseases. Int J Hematol,2010,91(1):20-29.
[28] Zander CB,Cao W,Zheng XL.ADAMTS13 and von Willebrand factor interactions. Curr Opin Hematol,2015,22(5):452-459.
[29] Aster RH.Pooling of platelets in the spleen: role in the pathogenesis of“hypersplenic” thrombocytopenia. J Clin Invest,1966,45(5):645-657.
[30] Shahab N,Evans ML.Images in clinical medicine. Platelet satellitism. N Engl J Med,1998,338(9):591.
[31] Sultan S,Irfan SM.Platelet satellitism: a spurious cause of thrombocytopenia in chronic liver disease. Eur J Haematol,2015,94(1):90-91.
[32] 潘圣红. 肝硬化并发假性血小板减少1例.临床合理用药杂志,2014,7(2):106.

Mechanisms of thrombocytopenia in liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[4]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[5]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[6]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[7]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[8]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[9]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[10]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[11]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[12]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.
[13]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.
[14]	Tang Chengwei. Chronic liver disease and thrombocytopenia：Changes in clinical management concept [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 457-458.
[15]	Han Meiling, Chen Ping. Antiviral therapy in patients with liver cirrhosis and thrombocytopenia [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 466-469.